Wyeth's Redux, Mazanor obesity treatments recommended for high risk patients -- guidelines.

Executive Summary

REDUX, PONDIMIN AMONG PHARMACOLOGIC THERAPIES RECOMMENDED FOR OBESE PATIENTS at "high, very high and extremely high health risk" in obesity treatment guidelines developed by the American Obesity Association and Shape Up America. "Dexfenfluramine is the first antiobesity agent approved" by FDA "for both weight loss and maintenance of weight loss," the guidance notes. The drug also has the "potential to provide an early indication of patient responsiveness, as an analysis of clinical data shows that 60% of patients who responded in the first four weeks of treatment lost 10% of their initial body weight after one year of treatment."